Thompson Siegel & Walmsley LLC Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Thompson Siegel & Walmsley LLC lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 17.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 230,159 shares of the specialty pharmaceutical company's stock after purchasing an additional 34,416 shares during the quarter. Thompson Siegel & Walmsley LLC owned about 1.09% of ANI Pharmaceuticals worth $13,731,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Sequoia Financial Advisors LLC purchased a new position in ANI Pharmaceuticals in the 2nd quarter valued at approximately $600,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $228,000. Boston Partners acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at $606,000. Global Alpha Capital Management Ltd. boosted its holdings in ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock valued at $32,005,000 after purchasing an additional 9,500 shares during the period. Finally, Renaissance Technologies LLC grew its stake in ANI Pharmaceuticals by 15.4% during the 2nd quarter. Renaissance Technologies LLC now owns 156,802 shares of the specialty pharmaceutical company's stock worth $9,985,000 after purchasing an additional 20,900 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ANIP. HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research note on Tuesday, October 22nd. StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. Finally, Raymond James boosted their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $77.33.

ANI Pharmaceuticals Stock Up 1.2 %

NASDAQ:ANIP traded up $0.68 during midday trading on Thursday, hitting $55.78. 89,073 shares of the company were exchanged, compared to its average volume of 218,662. ANI Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The company has a market capitalization of $1.17 billion, a PE ratio of -101.56 and a beta of 0.71. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a fifty day simple moving average of $58.35 and a 200 day simple moving average of $61.07.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.05 earnings per share. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.